Clinical Trial: BRAF V600E Mutations In Papillary Thyroid Carcinoma

Study Status: Completed
Recruit Status: Unknown status
Study Type: Interventional

Official Title: Association Of Prognosis And BRAF V600E Mutations In Papillary Thyroid Carcinoma

Brief Summary: The purpose of this study is to determine whether BRAF V600E mutation in our patients with papillary thyroid cancer has an association with poor prognosis.

Detailed Summary: Papillary thyroid carcinoma (PTC) is the most common type of thyroid malignancy and BRAF V600E mutation is the most common genetic alteration identified in PTC, ranging from 25 to 80%, with the average rate about 45%. Various studies demonstrated a relationship between BRAF V600E mutation and aggressive characteristics of the cancer, including the worse patient prognosis. But,there are no studies from Turkey regarding this topic. So the investigators will examine BRAF V600E mutation in our patients with PTC and try to assess the role of this mutation in prognosis and further management of the patients.
Sponsor: Bezmialem Vakif University

Current Primary Outcome: BRAF V600E MUTATION [ Time Frame: 2 years ]

Original Primary Outcome: Same as current

Current Secondary Outcome:

Original Secondary Outcome:

Information By: Bezmialem Vakif University

Dates:
Date Received: July 6, 2011
Date Started: July 2011
Date Completion: July 2012
Last Updated: August 13, 2011
Last Verified: August 2011